Foghorn Therapeutics (FHTX)

Foghorn Therapeutics Stock Analysis & Ratings

FHTX Stock Chart & Stats

Day’s Range$11.1 - $12.4908
52-Week Range$8.01 - $24.34
Previous Close$12.22
Average Volume (3M)147.06K
Market Cap$475.22M
P/E Ratio-4.5
Next EarningsAug 09, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score4
EPS (TTM)-2.72



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Foghorn Therapeutics’s price range in the past 12 months?
Foghorn Therapeutics lowest stock price was $8.01 and its highest was $24.34 in the past 12 months.
    What is Foghorn Therapeutics’s market cap?
    Foghorn Therapeutics’s market cap is $475.22M.
      What is Foghorn Therapeutics’s price target?
      The average price target for Foghorn Therapeutics is $25.00. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $25.00 ,the lowest forecast is $25.00. The average price target represents 118.15% Increase from the current price of $11.46.
        What do analysts say about Foghorn Therapeutics?
        Foghorn Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
          When is Foghorn Therapeutics’s upcoming earnings report date?
          Foghorn Therapeutics’s upcoming earnings report date is Aug 09, 2022 which is in 83 days.
            How were Foghorn Therapeutics’s earnings last quarter?
            Foghorn Therapeutics released its earnings results on May 09, 2022. The company reported -$0.65 earnings per share for the quarter, missing the consensus estimate of -$0.525 by -$0.125.
              Is Foghorn Therapeutics overvalued?
              According to Wall Street analysts Foghorn Therapeutics’s price is currently Undervalued.
                Does Foghorn Therapeutics pay dividends?
                Foghorn Therapeutics does not currently pay dividends.
                What is Foghorn Therapeutics’s EPS estimate?
                Foghorn Therapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Foghorn Therapeutics have?
                Foghorn Therapeutics has 41,470,000 shares outstanding.
                  What happened to Foghorn Therapeutics’s price movement after its last earnings report?
                  Foghorn Therapeutics reported an EPS of -$0.65 in its last earnings report, missing expectations of -$0.525. Following the earnings report the stock price went down -8.636%.
                    Which hedge fund is a major shareholder of Foghorn Therapeutics?
                    Among the largest hedge funds holding Foghorn Therapeutics’s share is Flagship Pioneering Inc.. It holds Foghorn Therapeutics’s shares valued at 193M.


                      Foghorn Therapeutics Stock Analysis

                      The Foghorn Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Foghorn Therapeutics

                      Foghorn Therapeutics Inc is engaged in discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, an untapped opportunity for therapeutic intervention. Its proprietary Gene Traffic Control platform gives us an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

                      Similar Stocks
                      No data currently available

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis